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p53 genotypes at the three polymorphic sites (intron 3,exon 4 codon 72, 
intron 6) and XRCC1-Arg399Gln exon 10 polymorphism was deter-
mined by a PCR-RFLP. Mutant p53 protein expression was detected in 
tumor of lung cancer by using immunohistochemical staining. 
Results: We found that aberrant p53 protein expression is positively 
correlated (p=0,03,CI95%=1,37-5,83) with null-genotypes of GSTM1 
and GSTT1 genes in lung cancer patients. Also, we found that function-
ally inactive genotypes of GST M1( p=0,023, CI95% =1,11-4,42) and 
GSTT1( p=0,077, CI95% =0,94-3,6) genes are associated with lymph 
node involved lung cancer patients.
In parallel, we observed that lung cancer risk was signiﬁcantly in-
creased at the presence of Gln/Gln genotype (homozygous on mi-
nor-variant allele) of XRCC1 gene ( p=0,03, CI95%= 1.00-3.49) and 
decreased for individuals bearing Arg/Gln genotype (p=0,01, CI95%= 
0.34-0.94). To further explore the role of XRCC1 and p53 genes 
polymorphism in lung cancer risk we found high frequency of the 
combination XRCC1/p53(in3/ex4/in6) [M/M]/[W/W-W/W-W/W] from 
lung cancer patients against control subject (12% and 4%, respectively, 
p=0,05,CI95%=1,00-10,32).
Discussion: Our results suggest the role of null-GST genes in lung 
cancer progression. We found that Gln/Gln genotype of XRCC1 gene 
at the presence of combination wild -type genotypes of p53 gene may 
be considered as important genetic event in the development of lung 
cancer, because the XRCC1-399Gln allele is associated with lower 
efﬁciency of DNA repair and play critical role in the successful DNA 
repair.
Conclusion: Data obtained suggest that the polymorphism in metabolic 
enzymes (GSTT1 and GSTM1) and DNA repair (XRCC1) genes may 
affect risk and progression of lung cancer due to their inﬂuence on p53 
function. 
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Background: The organic anion transporting polypeptide (OATP) 1B1 
is a drug uptake transporter located at the basolateral membrane of 
hepatocyte. Here we investigated the association of single nucleotide 
polymorphisms (SNP) in the SLCO1B1 gene encoding for OATP1B1 
with irinotecan-pharmacokinetics, toxicity and survival of patients with 
advanced non-small cell lung cancer (NSCLC). 
Methods: Peripheral blood samples from 81 NSCLC patients prospec-
tively enrolled in a phase II study of irinotecan and cisplatin chemo-
therapy were used for genotyping SLCO1B1 -11187G>A, 388A>G, 
and 521T>C. 
Results: Patients with the 521C allele showed a trend for higher SN-38 
AUC (p=0.054) compared to those without this allele. When haplo-
types were assigned, patients with at least one *15 haplotype (contain-
ing 388A>G and 521T>C variants) showed signiﬁcantly higher SN-38 
AUC than noncarriers (p=0.009). The most common severe toxicity 
was NCI-CTC grade 4 neutropenia (G4N), which occurred in 22 (27%) 
patients. Patients with 521C allele showed higher incidence of G4N and 
lower delivered dose of irinotecan (p=0.047) than those without this 
allele. Patients with the -11187A allele also showed a trend for higher 
G4N (p=0.057) and lower delivered dose of irinotecan (p=0.029). 
Grade 3 diarrhea was developed in 8 (10%) patients those with the 
388GG genotype (p=0.046). In survival analysis, patients with *1b/*1b 
diplotype showed worse overall survival than others (p=0.004), which 
was retained in multivariate analysis. 
Conclusions: These ﬁndings suggest that OATP1B1 variants are 
involved in transporting SN-38 and highly predictive for toxicity and 
prognosis of NSCLC patients treated with irinotecan-based chemo-
therapy.
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Background: To investigate whether ABCB1, ABCC2, and ABCG2 
genetic polymorphisms affect pharmacokinetics (PK) of irinotecan 
and treatment outcome of patients with advanced non-small cell lung 
cancer (NSCLC).
Methods: Blood samples from 107 NSCLC patients treated with iri-
notecan and cisplatin chemotherapy were used for genotyping ABCB1 
(1236C>T, 2677G>T/A, 3435C>T), ABCC2 (-24C>T, 1249G>A, 
3972C>T), and ABCG2 (34G>A, 421C>A) polymorphisms. Geno-
types were correlated with irinotecan PK, toxicity, tumor response, and 
survival.
Results: Among 8 polymorphisms, 3435TT and 2677TT were associ-
ated with SN-38G AUC and SN-38G clearance. When haplotypes are 
assigned, 2677TT/3435TT carriers showed signiﬁcantly lower SN-38G 
AUC (P=0.006), whereas, 2677GG/3435CC carriers showed signiﬁ-
cantly higher SN-38 AUC (P =0.039). These ﬁndings suggest that 
2677TT and 3435TT variants are associated with higher efﬂux activity. 
In toxicity, the 2677G/T or A was associated with grade 4 neutropenia. 
The 2677GG carriers showed signiﬁcantly lower absolute neutrophil 
count during the 1st cycle (p=0.012) as well as entire course of chemo-
therapy (p=0.042). The 3435TT was associated with higher frequency 
of grade 3 diarrhea (p=0.047). In tumor response, ABCC2 -24TT and 
3972TT genotypes were associated with higher response rates (p=0.031 
and 0.046, respectively) and longer progression-free survival (p=0.035 
and 0.038, respectively), which was sustained in haplotype analysis. 
Conclusions: Speciﬁc polymorphisms of ABCB1 and ABCC2 can 
inﬂuence the disposition and tumor response to irinotecan by regulating 
transporter activity. These ﬁndings may help to individualize irinote-
can-based chemotherapy in patients with advanced NSCLC.
